Anglin Dent
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anglin Dent has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Phedias Diamandis
Department of Laboratory Medicine and Pathobiology University of Toronto Toronto Ontario Canada
3 shared publications - Alberto J. Leon
Princess Margaret Cancer Centre, 101 College Street, Toronto, ON M5G 1L7, Canada
2 shared publications - Kevin Faust
Princess Margaret Cancer Centre Toronto Ontario Canada
2 shared publications - Queenie Tsang
Princess Margaret Cancer Centre, 101 College Street, Toronto, ON M5G 1L7, Canada
2 shared publications - Amit Manulal Oza
Princess Margaret Cancer Centre 2 Division of Medical Oncology and Hematology , Toronto, Canada
1 shared publication - Andrew Gao
Laboratory Medicine Program, University Health Network, Toronto, Canada
1 shared publication
Latest Publications
- Open Access
- 20 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Systematic review and meta-analysis of machine learning models predicting massive hemorrhage protocol in trauma
Timely activation of massive hemorrhage protocols (MHP) is critical to prevent exsanguination and improve survival in trauma patients. Current clinical tools for predicting MHP need have limited sensitivity and moderate specificity. Machine learning (ML) models may enhance early recognition of life-threatening hemorrhage. We conducted a systematic review and meta-analysis of studies that developed or validated ML models to predict MHP need in patients with traumatic injuries (PROSPERO CRD42024574891). Databases searched included MEDLINE, EMBASE, Web of Science, the Cochrane Central Register of Controlled Trials, and LILACS. Risk of bias was assessed with PROBAST, a funnel plot and Deeks’ statistical test, and the GRADE checklist. Of the 4542 abstracts screened, 21 studies (50 ML models) were included. The ML model types with the highest pooled AUROC were random forest (0.89, 95% CI 0.85–0.93), neural networks (0.88, 95% CI 0.83–0.93), and XGBoost Models (0.86, 95% CI 0.80–0.93), all of which commonly outperforming their non-ML comparator. Despite superior discrimination, most ML models lacked robust subgroup performance evaluation, external validation, or feasibility for clinical deployment. The median APPRAISE-AI methodologic quality score was 51 out of 100 (Interquartile range [IQR]: 46, 55). Further, model reporting quality (TRIPOD + AI) was moderate; no study achieved full points across all 27 reporting items. Risk of bias was frequently high or unclear. Thus, pooled performance metrics should be interpreted with caution, as they may be influenced by methodological weaknesses in the underlying studies. These findings underscore the need for more rigorously designed and transparently reported ML studies in trauma care. Realizing the potential of ML for supporting MHP delivery in trauma care will require further collaborative, clinically grounded model development with robust validation, transparent reporting, and a focus on real-world deployment to translate predictive performance into improved patient outcomes. PROSPERO Registration Number: CRD42024574891.
- 20 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessSystematic review and meta-analysis of machine learning models predicting massive hemorrhage protocol in trauma
Timely activation of massive hemorrhage protocols (MHP) is critical to prevent exsanguination and improve survival in trauma patients. Current clinical tools for predicting MHP need have limited sensitivity and moderate specificity. Machine learning (ML) models may enhance early recognition of life-threatening hemorrhage. We conducted a systematic review and meta-analysis of studies that developed or validated ML models to predict MHP need in patients with traumatic injuries (PROSPERO CRD42024574891). Databases searched included MEDLINE, EMBASE, Web of Science, the Cochrane Central Register of Controlled Trials, and LILACS. Risk of bias was assessed with PROBAST, a funnel plot and Deeks’ statistical test, and the GRADE checklist. Of the 4542 abstracts screened, 21 studies (50 ML models) were included. The ML model types with the highest pooled AUROC were random forest (0.89, 95% CI 0.85–0.93), neural networks (0.88, 95% CI 0.83–0.93), and XGBoost Models (0.86, 95% CI 0.80–0.93), all of which commonly outperforming their non-ML comparator. Despite superior discrimination, most ML models lacked robust subgroup performance evaluation, external validation, or feasibility for clinical deployment. The median APPRAISE-AI methodologic quality score was 51 out of 100 (Interquartile range [IQR]: 46, 55). Further, model reporting quality (TRIPOD + AI) was moderate; no study achieved full points across all 27 reporting items. Risk of bias was frequently high or unclear. Thus, pooled performance metrics should be interpreted with caution, as they may be influenced by methodological weaknesses in the underlying studies. These findings underscore the need for more rigorously designed and transparently reported ML studies in trauma care. Realizing the potential of ML for supporting MHP delivery in trauma care will require further collaborative, clinically grounded model development with robust validation, transparent reporting, and a focus on real-world deployment to translate predictive performance into improved patient outcomes. PROSPERO Registration Number: CRD42024574891.
- Open Access
- 29 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (39) , eadg1894
HAVOC: Small-scale histomic mapping of cancer biodiversity across large tissue distances using deep neural networks
Intratumoral heterogeneity can wreak havoc on current precision medicine strategies because of challenges in sufficient sampling of geographically separated areas of biodiversity distributed across centimeter-scale tumor distances. To address this gap, we developed a deep learning pipeline that leverages histomorphologic fingerprints of tissue to create “Histomic Atlases of Variation Of Cancers” (HAVOC). Using a number of objective molecular readouts, we demonstrate that HAVOC can define regional cancer boundaries with distinct biology. Using larger tumor specimens, we show that HAVOC can map biodiversity even across multiple tissue sections. By guiding profiling of 19 partitions across six high-grade gliomas, HAVOC revealed that distinct differentiation states can often coexist and be regionally distributed within these tumors. Last, to highlight generalizability, we benchmark HAVOC on additional tumor types. Together, we establish HAVOC as a versatile tool to generate small-scale maps of tissue heterogeneity and guide regional deployment of molecular resources to relevant biodiverse niches.
- 29 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (39) , eadg1894
Open AccessHAVOC: Small-scale histomic mapping of cancer biodiversity across large tissue distances using deep neural networks
Intratumoral heterogeneity can wreak havoc on current precision medicine strategies because of challenges in sufficient sampling of geographically separated areas of biodiversity distributed across centimeter-scale tumor distances. To address this gap, we developed a deep learning pipeline that leverages histomorphologic fingerprints of tissue to create “Histomic Atlases of Variation Of Cancers” (HAVOC). Using a number of objective molecular readouts, we demonstrate that HAVOC can define regional cancer boundaries with distinct biology. Using larger tumor specimens, we show that HAVOC can map biodiversity even across multiple tissue sections. By guiding profiling of 19 partitions across six high-grade gliomas, HAVOC revealed that distinct differentiation states can often coexist and be regionally distributed within these tumors. Last, to highlight generalizability, we benchmark HAVOC on additional tumor types. Together, we establish HAVOC as a versatile tool to generate small-scale maps of tissue heterogeneity and guide regional deployment of molecular resources to relevant biodiverse niches.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1685
Abstract 1685: Deep learning approaches to deciphering intra-tumoural heterogeneity in glioblastoma
BACKGROUND: Emerging evidence strongly implicates intra-tumoral heterogeneous biology in treatment resistance and disease progression across many cancer types. Thus, there is a need for workflows capable of systematically resolving and targeting distinct tumor subpopulations1. Using glioblastoma (GBM) as a prototype, I have aimed to leverage the computational power of Artificial Intelligence (AI) and deep learning to develop an autonomous workflow for the objective definition of biologically distinct tumor subpopulations2. OBJECTIVES: I hypothesize that AI may be leveraged as a tool to resolve spatial heterogeneity, by identifying tumoral subpopulations with unique molecular profiles and therapeutic targets. To highlight the need for routine analysis of tumor heterogeneity, I will address if: METHODS: I apply our developed image clustering workflows to quantify AI-defined subregions within a clinical cohort of 10 GBM patient tumors2,3. Laser capture microdissection and mass spectrometry-based proteomics are leveraged to address if AI-defined subregions show intra-tumoral molecular variation. Further, existing pharmacogenomic databases are utilized to carry out drug sensitivity and transcriptional clustering to define AI-defined region-specific therapeutic sensitivities and resistances across my clinical GBM cohort4. RESULTS: Preliminary data shows that region to region heterogeneity can be found in IDH wild-type GBM using our unbiased omics approach, in addition to predicting different pharmacogenomic sensitivities. CONCLUSIONS: This project aims to develop the first AI-driven tool to guide the routine and systematic molecular analysis of spatial morphogenomic heterogeneity. Further, this tool may have the potential to provide novel approaches for personalized care by selecting drug combinations that target a larger fraction of a tumor’s true biology. 1. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (80-. ). 344, 1396-1401 (2014). 2. Faust, K. et al. Unsupervised Resolution of Histomorphologic Heterogeneity in Renal Cell Carcinoma Using a Brain Tumor-Educated Neural Network. JCO Clin. Cancer Informatics 811-821 (2020) doi:10.1200/cci.20.00035. 3. Roohi, A., Faust, K., Djuric, U. & Diamandis, P. Unsupervised Machine Learning in Pathology: The Next Frontier. Surgical Pathology Clinics vol. 13 349-358 (2020). 4. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity. Nat. 2012 4837391 483, 603-607 (2012). Citation Format: Anglin J. Dent, Kevin Faust, Brian Lam, Alberto J. Leon, Queenie Tsang, Phedias Diamandis. Deep learning approaches to deciphering intra-tumoural heterogeneity in glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1685.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1685
Open AccessAbstract 1685: Deep learning approaches to deciphering intra-tumoural heterogeneity in glioblastoma
BACKGROUND: Emerging evidence strongly implicates intra-tumoral heterogeneous biology in treatment resistance and disease progression across many cancer types. Thus, there is a need for workflows capable of systematically resolving and targeting distinct tumor subpopulations1. Using glioblastoma (GBM) as a prototype, I have aimed to leverage the computational power of Artificial Intelligence (AI) and deep learning to develop an autonomous workflow for the objective definition of biologically distinct tumor subpopulations2. OBJECTIVES: I hypothesize that AI may be leveraged as a tool to resolve spatial heterogeneity, by identifying tumoral subpopulations with unique molecular profiles and therapeutic targets. To highlight the need for routine analysis of tumor heterogeneity, I will address if: METHODS: I apply our developed image clustering workflows to quantify AI-defined subregions within a clinical cohort of 10 GBM patient tumors2,3. Laser capture microdissection and mass spectrometry-based proteomics are leveraged to address if AI-defined subregions show intra-tumoral molecular variation. Further, existing pharmacogenomic databases are utilized to carry out drug sensitivity and transcriptional clustering to define AI-defined region-specific therapeutic sensitivities and resistances across my clinical GBM cohort4. RESULTS: Preliminary data shows that region to region heterogeneity can be found in IDH wild-type GBM using our unbiased omics approach, in addition to predicting different pharmacogenomic sensitivities. CONCLUSIONS: This project aims to develop the first AI-driven tool to guide the routine and systematic molecular analysis of spatial morphogenomic heterogeneity. Further, this tool may have the potential to provide novel approaches for personalized care by selecting drug combinations that target a larger fraction of a tumor’s true biology. 1. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (80-. ). 344, 1396-1401 (2014). 2. Faust, K. et al. Unsupervised Resolution of Histomorphologic Heterogeneity in Renal Cell Carcinoma Using a Brain Tumor-Educated Neural Network. JCO Clin. Cancer Informatics 811-821 (2020) doi:10.1200/cci.20.00035. 3. Roohi, A., Faust, K., Djuric, U. & Diamandis, P. Unsupervised Machine Learning in Pathology: The Next Frontier. Surgical Pathology Clinics vol. 13 349-358 (2020). 4. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity. Nat. 2012 4837391 483, 603-607 (2012). Citation Format: Anglin J. Dent, Kevin Faust, Brian Lam, Alberto J. Leon, Queenie Tsang, Phedias Diamandis. Deep learning approaches to deciphering intra-tumoural heterogeneity in glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1685.
- 6 May 2022
- Published by Wiley in The Journal of Pathology
- Vol. 257 (4) , 445-453
Integrating computational pathology and proteomics to address tumor heterogeneity
Despite numerous advances in our molecular understanding of cancer biology, success in precision medicine trials has remained elusive for many malignancies. Emerging evidence now supports that these challenges are partly driven by proteogenomic discordances across molecular readouts and heterogeneous biology that is spatially distributed across tumors. Here we discuss these key limitations and how integrating the promise of mass‐spectrometry‐based global proteomics and computational imaging can help prioritize and direct regional sampling to help overcome these important challenges of biologic variation in cancer. © 2022 The Pathological Society of Great Britain and Ireland.
- 6 May 2022
- Published by Wiley in The Journal of Pathology
- Vol. 257 (4) , 445-453
Integrating computational pathology and proteomics to address tumor heterogeneity
Despite numerous advances in our molecular understanding of cancer biology, success in precision medicine trials has remained elusive for many malignancies. Emerging evidence now supports that these challenges are partly driven by proteogenomic discordances across molecular readouts and heterogeneous biology that is spatially distributed across tumors. Here we discuss these key limitations and how integrating the promise of mass‐spectrometry‐based global proteomics and computational imaging can help prioritize and direct regional sampling to help overcome these important challenges of biologic variation in cancer. © 2022 The Pathological Society of Great Britain and Ireland.